Clinical and economic benefits of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for prevention of RSV illness in infants: A cost-effectiveness analysis for Singapore | Synapse
March 3, 2026
Clinical and economic benefits of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for prevention of RSV illness in infants: A cost-effectiveness analysis for Singapore
Key Points
Cost-effectiveness of the bivalent vaccine may improve infant health outcomes against RSV illness,
The analysis indicates a potential cost reduction of 25% in hospitalizations due to RSV in infants with maternal vaccination,
Evaluated through a cost-effectiveness analysis comparing the bivalent maternal vaccine with routine care for RSV prevention,
Results support the wider implementation of the maternal vaccine, highlighting its potential to reduce healthcare burdens on families.